volrustomig + rilvegostomig + bevacizumab

This is a combination of three agents: - **Volrustomig**: a bispecific monoclonal antibody targeting both PD-1 and CTLA-4, designed to synergistically enhance antitumor immune responses through immune checkpoint blockade. - **Rilvegostomig**: a bispecific monoclonal antibody targeting PD-1 and TIGIT, aiming to enhance T-cell activation and diminish immunosuppressive signaling in the tumor microenvironment. - **Bevacizumab**: a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor blood supply. This combination is under clinical investigation for advanced solid tumors, including hepatocellular carcinoma and gastric/gastroesophageal junction adenocarcinoma, aiming to potentiate immunotherapy and anti-angiogenic effects for improved antitumor efficacy[1][5].